Alternatives to antibiotics – a pipeline portfolio review by Czaplewski, Lloyd et al.
 
 
Alternatives to antibiotics – a pipeline portfolio
review
Czaplewski, Lloyd; Bax, Richard; Clokie, Martha; Dawson, Mike; Fairhead, Heather; Fischetti,
Vincent A; Foster, Simon; Gilmore, Brendan F; Hancock, Robert E W; Harper, David;
Henderson, Ian; Hilpert, Kai; Jones, Brian V; Kadioglu, Aras; Knowles, David; Ólafsdóttir,
Sigríður; Payne, David; Projan, Steve; Shaunak, Sunil; Silverman, Jared
DOI:
10.1016/S1473-3099(15)00466-1
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Czaplewski, L, Bax, R, Clokie, M, Dawson, M, Fairhead, H, Fischetti, VA, Foster, S, Gilmore, BF, Hancock,
REW, Harper, D, Henderson, IR, Hilpert, K, Jones, BV, Kadioglu, A, Knowles, D, Ólafsdóttir, S, Payne, D,
Projan, S, Shaunak, S, Silverman, J, Thomas, CM, Trust, TJ, Warn, P & Rex, JH 2016, 'Alternatives to
antibiotics – a pipeline portfolio review', The Lancet Infectious Diseases, vol. 16, no. 2, pp. 239–251.
https://doi.org/10.1016/S1473-3099(15)00466-1
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked Feb 2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Lancet ID Manuscript July 2015 1 of 17 
FULL REVIEW DRAFT 
Alternatives to antibiotics – a pipeline portfolio review  
Lloyd Czaplewski, Richard Bax, Martha Clokie, Mike Dawson, Heather Fairhead, Vincent A. Fischetti, Simon 
Foster, Brendan F. Gilmore, Robert E.W. Hancock, David Harper, Ian R. Henderson, Kai Hilpert, Brian V 
Jones, Aras Kadioglu, David Knowles, Sigríður Ólafsdóttir, David Payne, Steve Projan, Sunil Shaunak, Jared 
Silverman, Christopher M. Thomas, Trevor Trust, Peter Warn, John H. Rex. 
Dr Lloyd Czaplewski PhD; Chemical Biology Ventures Ltd. Abingdon, UK, Abgentis Ltd, Birmingham, UK 
and Persica Pharmaceuticals Ltd, Canterbury, UK.  Dr Richard Bax MD; Transcrip Partners LLP. Reading, UK. 
Dr Martha Clokie PhD; Dept. of Infection, Immunity and Inflammation, University of Leicester, UK. Dr Mike 
Dawson PhD; Novacta Biosystems Ltd. Welwyn Garden City, UK and Cantab Anti-infectives Ltd. Welwyn 
Garden City, UK. Dr Heather Fairhead PhD; Phico Therapeutics Ltd. Babraham, UK. Professor Vincent A. 
Fischetti PhD; Laboratory of Bacterial Pathogenesis and Immunology. The Rockefeller University, New York, 
USA. Professor Simon Foster PhD; Department of Molecular Biology and Biotechnology, University of 
Sheffield, Sheffield. UK and Absynth Biologics Ltd. Liverpool, UK. Dr Brendan F Gilmore PhD; School of 
Pharmacy, Queen’s University, Belfast. UK. Professor Robert E.W. Hancock PhD; Department of Microbiology 
and Immunology. University of British Columbia, Vancouver, Canada. Dr David Harper PhD; .AmpliPhi 
Biosciences Corporation, Richmond, Virginia, USA. Professor Ian Henderson PhD; Institute of Microbiology 
and Infection, University of Birmingham, UK. Dr Kai Hilpert PhD; Institute of Infection and Immunity, St 
Georges, University of London. UK., TiKa Diagnostics Ltd. UK. Dr Brian Jones PhD; Pharmacy and 
Biomolecular Sciences, University of Brighton UK and Queen Victoria Hospital NHS Foundation Trust, East 
Grinsted, UK. Professor Aras Kadioglu PhD; Institute of Infection and Global Health, University of Liverpool, 
UK. Dr David Knowles PhD; Procarta Biosystems Ltd. Norwich, UK and Absynth Biologics Ltd. Liverpool, 
UK. Dr Sigríður Ólafsdóttir PhD; Icelandic Medicines Agency, Reykjavik, Iceland. Dr David Payne PhD; 
GlaxoSmithKline, Collegeville, PA, USA. Dr Steve Projan PhD; MedImmune, Washington D.C. USA. 
Professor Sunil Shaunak MD; Department of Medicine. Imperial College, London. UK. Dr Jared Silverman 
PhD; Cubist Pharmaceuticals, Lexington, MA. USA. Professor Christopher M. Thomas PhD; Institute of 
Microbiology and Infection, University of Birmingham, UK and Plasgene Ltd. UK, Dr Trevor Trust PhD; Pan-
Provisonal Vaccine Inc. Canada. Dr Peter Warn PhD; Evotec Ltd, Manchester, UK. Dr John H. Rex MD; 
AstraZeneca, Boston, MA USA and F2G Ltd, Manchester, UK. 
Correspondence to: Dr Lloyd Czaplewski, Chemical Biology Ventures Ltd. 123 Alexander Close, Abingdon. 
OX14 1XD. UK. Lloyd.czaplewski@chembioventures.com 
Lancet ID Manuscript July 2015 2 of 17 
Abstract 
For 70 years antibiotics have saved countless lives and enabled the development of modern medicine, but it is 
becoming clear that the success of antibiotics may have only been temporary and we now anticipate a long-term, 
generational and perhaps never-ending challenge to find new therapies to combat antibiotic resistant bacteria. As 
the search for new conventional antibiotics has become less productive and there are no clear strategies to 
improve success, a broader approach to address bacterial infection is needed. This review of potential 
alternatives to antibiotics (A2As) was commissioned by the Wellcome Trust and jointly funded by the 
Department of Health, involving scientists and physicians from academia and industry, has identified 20 A2A 
approaches now being actively explored. The feasibility and potential clinical impact of each approach was 
considered. The most advanced approaches (and the only ones likely to deliver new treatments by 2025) are 
antibodies, probiotics, and vaccines now in Phase II and Phase III trials. These new agents will likely target  P. 
aeruginosa, C. difficile and S. aureus. However, other than probiotics for C. difficile, this first wave will likely 
serve best as adjunctive or preventive therapies. This means that conventional antibiotics will still be needed. 
The economics of pathogen-specific therapies must improve soon to encourage innovation and greater 
investment into A2As with broad-spectrum activity (e.g. antimicrobial-, host defense- and, anti-biofilm 
peptides). Increased funding, estimated at >£1.5 bn over 10 years is required to validate, develop and exploit 
these A2As. Investment needs to be partnered with translational expertise and targeted support to validate these 
approaches to Phase II proof of concept.  Such an approach could transform our understanding of A2As as 
effective new therapies and should provide the catalyst required for both active engagement and investment by 
the pharma/biotech industry. Only a sustained, concerted and coordinated international effort with funding akin 
to space exploration will provide the answers needed for the next decade. 
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Introduction 
Given the rapidly rising tide of antibacterial resistance and the very limited pipeline of conventional 
antibacterial agents, a review, delivered by a working party of 24 scientists from academia and industry was 
commissioned by the Wellcome Trust and jointly funded by the Department of Health to consider the prospects 
for alternatives to antibiotics (A2As). While there have been technical reviews of individual alternative 
approaches,1 this review seeks to define the current state of A2As at the portfolio level, prioritise approaches, 
and provide evidence-based expectations for their delivery in order to inform funding decisions and policy in 
this crucial area of healthcare. 
Search strategy and selection criteria 
A2As were defined as non-compound approaches that target bacteria or approaches that target the host. Thus an 
antibody targeting a virulence factor or quorum sensing would be included but a compound targeting these 
processes would not.2,3 Biologicals or compounds targeting the host were included. This review focused on 
therapies that could be developed to treat systemic/invasive rather than superficial infections and is therefore 
limited to therapies that are administered orally, by inhalation or by injection. External topical administration 
was beyond its scope. The primary objective was to identify and review prospective therapeutic replacements 
for antibiotics. Alternatives that could be used in combination with conventional antibiotics and prophylactic 
approaches were also considered. 
The review benefited from non-confidential information on projects provided by its members and their 
knowledge base which was used to identify projects and companies, key publications and provision of expert 
project summaries to inform the working party. Additional preclinical and clinical projects were identified 
through a series of searches of PubMed, the internet using Google and ClinTrials.gov up to 27 February 2015, 
by use of key terms such as “antibody”, “probiotic”, “lysin”, “bacteriophage”, “vaccines”, “antimicrobial 
peptide”, “lantibiotic”, “host defense peptide”, “innate defense peptide”,  “antibiofilm peptide”, 
“immunomodulation”, immune stimulation”, “immune suppression”, “vaccine”, “liposome”, “chelation” and, if 
necessary, their use with “E. coli OR P. aeruginosa OR K. pneumoniae OR A. baumanii OR C. difficile OR S. 
aureus OR infection OR bacteria” followed by inspection of the papers and top 30 websites listed. Once 
proteins or compounds (Tables 1 and 2) and the organization developing them has been identified, their names 
were used for additional searches e.g. “Merck”. “MedImmune”, “Aridis”, “Seres”, “Rebiotix”, “Shire”, 
“Viropharma”, “Intron Biotechnology”, “Contrafect”, Ampliphi”, “Phico”, “Akthelia”, “Sanofi Pasteur”, 
“Valneva”, “Pfizer”, “Roche”, “Novacta”, “Adenium” and the associated company website overview, pipeline 
and news pages. The state of alternative project pharmacology was assessed by searches of PubMed for articles 
to 27 February 2015 by use of terms “pharmacokinetic OR safety” with “human OR mouse OR rat” in 
combination with “host defense peptide”; Antibiofilm peptide”; “lantibiotic”; bacteriophage”; “lysin” and in the 
case of antimicrobial peptides “antimicrobial peptide” with “pharmacokinetic OR safety” and “E. coli OR P. 
aeruginosa OR C. difficile OR S. aureus” followed by inspection of the 238 papers listed. We also reviewed 
studies cited in articles identified by this search and included them when relevant.  
The review considered 1. Feasibility of informative trials; 2. Magnitude of medical potential; 3. Likelihood and 
consequences of resistance; 4. Level of current research activity; 5. Likely timeline to registration, and 6. 
Activities that might enable validation and progression. The review process comprised (a) preparation of a ~50-
page working document summarising 20 current A2A, (b) a meeting to review and prioritise approaches, and (c) 
collective preparation of a report for the funders which is summarised in this review. This allowed the group to 
compile and share broad and well-informed views on the state-of-the-art for A2As with a wider community. 
Editorial control of the report was the responsibility of a sub-group without conflicts of interest (LC, BFG, IRH, 
BVJ, AK, H-HK, SO, SS, TT and JHR).  
The portfolio of alternative approaches 
The working party identified 20 approaches for consideration and recognised that the list may be incomplete 
(Tables 1 and 2). Projects were not reviewed in sufficient detail to make individual funding recommendations. 
The technical feasibility and clinical potential of the approaches were considered but the commercial 
attractiveness, potential return on investment or potential for reimbursement were not. Given the wide range of 
views within the group, this review does not represent a unanimous consensus. We recognise perspectives 
differ, that there are gaps in available data, and that science will continue to advance. This means that this 
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review should be taken as a snapshot of A2As and their perceived potential. Ten alternatives were prioritised 
and considered in more detail (Table 1). The other 10 approaches were not prioritised at this time because (i) 
other projects were considered more advanced in the translational pipeline; (ii) there was insufficient peer-
reviewed information to assess their potential clinical impact, feasibility, or safety (Table 2). Regular review of 
the portfolio at 2-year intervals is recommended. 
The potential of the top 10 approaches, with the exception of the recently discovered antibiofilm peptides, has 
been known for more than a decade but has not led to therapeutic products.90 This is an emerging field. For 
instance, there appear to be only 5 published pharmacology studies (two for Plectasin, two for lantibiotics and 
one for cyclic peptides) in the antimicrobial peptide field, and one published preclinical safety study across the 
field of Lysin, Bacteriophage, Antimicrobial-, Host Defense- and, Antibiofilm- Peptides.91-96  While there have 
been A2As clinical studies, the associated preclinical characterisation remains proprietary with insufficient 
published peer-reviewed evidence to understand the pharmacokinetic, pharmacodynamic, toxicology and safety 
strengths and liabilities of these approaches. This increases risk and averts funding. However, failure of the first 
clinical studies should not be allowed to block future exploitation. Indeed, many of the barriers to the 
development of these alternative strategies also exist for the development of novel small molecule antibiotics.  
The top 10 approaches, which the working party considered merited attention now were placed into two tiers. 
The focus within Tier 1 was on clinical development and in Tier 2 on preclinical development over the next 5 
years. Success of Tier 1 projects in Phase II and Phase III studies could transform the perception of the A2As 
portfolio. Access to funding through key preclinical and clinical development steps (e.g. production and 
characterisation, formulation, pharmacokinetics and pharmacodynamics, toxicology and safety pharmacology) 
with subsequent publications showing how these data support continued drug development was considered to be 
critical to progress towards clinical validation and to build confidence in the field. Supported studies should 
define and test clear go/no-go decision points for product progression. Primarily in vitro programmes of work or 
those focused entirely on surrogate endpoints e.g. characterising cytokines rather than pathology or 
microbiology may not be competitive. Application of “major pharma” development resources and expertise will 
be critical to validation and progression of A2As in a timely manner. Reliance on the academic and biotech 
communities alone may not not be sufficient to provide new products within a decade. 
Based on a combination of high clinical impact and high technical feasibility, the approaches anticipated to have 
the greatest potential to provide A2As were: (a) Phage Lysins as replacements; (b) Vaccines as prophylactics; 
(c) Antibodies as prophylactics, and (d) Probiotics as treatments or prophylactics for Clostridium difficile- and 
antibiotic- associated diarrhoea (CDAD/AAD). Bacteriophages (Wild-type and Engineered) were also 
considered to have potentially high impact as replacements but the feasibility of their entry into the market was 
unclear. Selected Immune Stimulation approaches were considered feasible as prophylactics or adjuncts to 
conventional treatments but their clinical impact was also unclear at this time.  
A2As portfolio analysis 
To enable an evidence-based review of the current state of development and likelihood of success of the 
prioritised alternative approaches, extensive internet searching and the knowledge base within the working party 
were used to define the breadth (number of projects and targets) and depth (current phase of development) of the 
A2As portfolio. In particular, company websites and news releases were used to identify projects currently (Q1 
2015) being actively progressed (Table 3). 
Industry standard timelines for clinical development phases, Phase I - 1 year,  Phase II - 2 years, Phase III - 3 
years, and Registration - 1 year were used to estimate the earliest likely date of product registration. 97–100  The 
estimated year of registration will likely differ from a particular sponsor’s estimates or project timelines. Host 
Defence Peptides and Antibiofilm Peptides were excluded because they were too early for this analysis.  
Similarly, industry-standard probabilities of success across projects in different phases of development; 
preclinical to Phase I – 23%, Phase 1 – 45%, Phase II – 47%, Phase III – 71%, and Registration – 90%, were 
applied.97–100 The estimates of the probability of success for individual projects within the class were summed. 
Values >100% indicate that there are sufficient project numbers and/or project maturity to anticipate that at least 
one product could be registered if access to sufficient funding and skilled development resources is provided.  
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Industry standard costs for clinical development phases: Phase I - £6m, Phase II - £10m, Phase III - £45m, and 
Registration – £1.3m were used to estimate the cost of portfolio projects. 97–100  These estimated costs will likely 
differ from a particular sponsor’s estimates. 
This uniform approach was taken because (a) similar levels of project planning data are not available for all 
projects, (b) when available, project-specific timelines developed by sponsors often shift, and (c) use of standard 
timelines allows uniform (re)calculation of the data as required. 
The strength of this type of analysis is that it removes any personal bias but its weakness is that it is almost 
always incorrect in the specifics of its details. 
Analysed by approach, the pipeline for Antibodies, Probiotics and Vaccines was sufficient to anticipate success 
as the probability of registration is >100%. However, for other alternative areas there are too few projects 
ongoing and/or they are currently too early to allow for anticipated project attrition. For instance, on the basis of 
the current portfolio, we cannot assume that Lysins, Bacteriophages or Antimicrobial Peptides will contribute to 
new therapies. 
It is important to note that most of the current novel activity is focused on C. difficile, P. aeruginosa and S. 
aureus only. The timeline analysis suggests that if successful, registrations might be: Antibodies – 2017; 
Probiotics – 2018; Vaccines – 2019; Immune Stimulants 2021; Lysins and Antimicrobial Peptides – 2022; 
Wild-type and Engineered Bacteriophages – 2023; and Host Defense and Antibiofilm peptides from 2027 
onwards.  
When analysed by pathogen, the ‘Probability of Success’ analysis indicates that if the alternative portfolio is 
adequately funded, we could expect two new products (Antibody, Probiotic or Vaccine) for CDAD/AAD by 
2019; one for P. aeruginosa (Antibody or Vaccine) by 2021, and one for S. aureus (Antibody, Lysin, or 
Vaccine) by 2022. The current portfolio lacks sufficient breadth and depth to anticipate multiple new products 
for these pathogens during this time frame. It is a matter of concern that there is little activity on the other 
ESKAPE pathogens (e.g., Enterococcus, Klebsiella, Acinetobacter or Enterobacter) or directed towards other 
Enterobacteriaceae. This means that it is most unlikely that A2As for these life threatening  pathogens will 
emerge in the next 10 years.   
As the portfolio advances through the later development phases, costs will increase and innovative funding 
arrangements will be required to maintain momentum given that most pharma companies have withdrawn from 
the “antibiotic area”.  
The working party recognised that by 2018/2019 we could anticipate observing success in multiple projects at 
Phase II and that this could encourage greater investment in the sector. New projects starting in 2018/2019 
might be expected to reach registration by 2030.  
The working party found that A2As have the potential to deliver clinical benefit but the scale of current activity 
and availability of funding will have to increase substantially to achieve that benefit. 
What will the portfolio cost? 
To estimate funding requirements, the named projects from Table 3 were budgeted to 2025 using industry 
standard costs for clinical development phases.  Although some organisations may currently aim to deliver with 
smaller budgets, the application of standard costs serves to reflect prior reality for delivery and to remove bias.  
The funds for the current phase of the project are assumed to be in place and committed. By adding the cost of 
each subsequent stage that each project has to pass up to registration and application of the risk estimates at each 
stage of development, as described above, the funds required to registration were calculated.73  
Where the alternative project portfolio is too thin or early to anticipate success, new funding is required to 
strengthen the portfolio. A key objective should be to test A2As at Phase II to validate the approach and to 
adequately understand the clinical potential of the approach it may be necessary to take several projects to Phase 
II. The Lysins, Bacteriophage and Antimicrobial Peptides approaches have advancing projects but too few 
projects to anticipate adequate testing of the concepts. They also require additional investment to build capacity 
and translational expertise to exploit their full potential. Allowing for anticipated project attrition, a pipeline to 
support the evaluation of a single project at Phase II would require 9 preclinical projects at £12.5 m/project over 
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5 years, leading to two Phase I and potentially one Phase II study at £135m. This funding recommendation is 
contingent on the results being peer reviewed and open access publication to provide the requisite evidence-base 
for informing future R&D. 
The Host Defence and Antibiofilm peptide approaches are innovative and have broad spectrum potential. It may 
be necessary to advance the first wave of these innovative projects beyond Phase II to validate the approaches 
and to convince pharma, investors and clinicians. A greater level of investment (£575m) would be required to 
build a pipeline of Host Defence Peptide and Antibiofilm Peptide projects because they are currently in an early 
stage of development. An estimated 34 preclinical projects are required to provide 8 Phase I and 4 Phase II 
studies to get at least one project through to Phase III and product registration (Table 4). There are several 
natural and synthetic Host Defense Peptides and Antibiofilm peptides as potential starting points.  Chemical 
modifications, hybrid peptides and chemical mimetics could be explored. Project creation and translational 
research and in this area could be accelerated by committing £85m/year for 5 years. This would provide a 
powerful incentive to build capacity and to progress towards clinical validation of these peptide based 
approaches. 
Our analysis assumes that funding for named projects of £221m is available to complete their progression 
through their current project phase. Additional risk adjusted funding of £469m will be required for subsequent 
phases and should support development of one new product for each of P. aeruginosa, C. difficile and S. aureus 
by 2022. This level of investment would enable validation of antibodies, probiotics, and novel vaccines as 
A2As.  
The Lysin, Bacteriophage and Antimicrobial Peptides portfolios needs to be increased in order to adequately test 
these approaches in a timely manner. This could be achieved with risk adjusted investment of £405m. Building 
an adequate Host Defense Peptide and Antibiofilm peptide portfolio will require £575m.  
The working party therefore identified ~£1.5 billion of risk-adjusted funding that will be required to validate and 
exploit the current 10 high priority A2As in a timely manner. We did not forecast the funding requirements for 
the remaining 10 approaches or for additional blue-sky activity to add to the pipeline in the future.  
Challenges to developing and deploying A2As 
1. Innovation must be linked to translation expertise.  
The innovators in this space (largely academics and biotechs) often lack industry-level development skills. 
Hence, increased funding needs to be partnered with investment in translational skills development. Alternative 
programmes may benefit from greater access to PK/PD, formulation, toxicology and manufacturing expertise. 
Provision of adequate funding for the multi-disciplinary teams and costs associated with the preclinical 
characterization of a lead candidate for clinical development will be a critical factor for success. Pre-competitive 
partnerships and the creation of development hubs might be one way to support this area. Implementation of US 
SBIR (Small Business Innovation Research)-like awards and calls to tender for and purchase desired research 
activities from biotech and pharma on behalf of the academic and SME/biotech alternative community is 
another innovative way to support this area. Such activities might encourage industry to become involved in a 
manner that develops both critical mass and sustainability. 
2. Clinical Trials 
Careful clinical trial design will be critical. Projects need to ensure that endpoints are relevant to both the patient 
and the physician, often but not necessarily exclusively based on endpoints grounded in how patients feel, 
function and survive. Unless the clinical signal is strong, there is a risk that the size and cost of the clinical trials 
required to demonstrate an incremental benefit will be too large for industry to support. Thus, it will be 
important to be willing to terminate projects if clinical success is either low probability or likely to have low 
impact. As with trials of new antibiotics, surrogate endpoints that are predictive of clinical efficacy should be 
included as secondary endpoints (e.g., changes in cytokine levels or changes in imaging of infections) but are 
unlikely to be acceptable as the basis for registration for high mortality life threatening infections. 
3. Economic models in this therapy area must be improved. 
In addition to adequate funding and expertise, development and deployment of alternative antibacterial 
medicines is dependent on a return on investment. The working party did not consider the economics of A2As  
but noted that replacing antibiotics will be a major challenge. At present, many of the A2As are pathogen- or 
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strain-specific. By comparison, most modern antibiotics have a broad spectrum of activity. For example, the 
recently approved combination of ceftolozane and tazobactam, for cIAI, cUTI and pyelonephritis, has clinical 
efficacy data for 10 pathogens including Klebsiella spp, Escherichia coli and Pseudomonas aeruginosa with 
clinical microbiology suggesting potential against another 20 pathogens.101,102 Multiple alternative therapies 
would be required to provide similar spectrum of coverage. We did not address the additional costs for the 
diagnostics that will also be required. In the first instance, A2As are likely to focus on the most prevalent 
infections and may provide sufficient clinical benefit to ensure a return on investment. At best, they will be a 
partial replacement for antibiotics.  
Innovative regulation:  
Innovative therapies may require innovative regulation but there is a risk that inexperienced developers may 
increase barriers to commercialisation by unnecessarily raising regulatory and clinical hurdles. Bacteriophage 
therapies currently in development are an example of the kind of product driving the evolution of regulatory 
approaches. Broad conversations about options for the unique challenges of each alternative are required: a 
recent workshop hosted by EMA on bacteriophage is an example of how this work needs to be progressed.  
3. Flexible delivery models: 
Some A2As could be delivered by different mechanisms to those for traditional antibiotics. Instead of a single 
global manufacturing pipeline, the development of localised services akin to blood transfusion or stem cell 
harvesting and transplantation could facilitate patient benefit and should be considered. For example, localised 
bacteriophage therapy attuned to patient need within a hospital might be an appropriate model for some 
products. 
4. One Health: the potential for alternatives in animal health 
All of the A2As have potential uses in animal health and demonstration of efficacy in companion and 
agricultural animals could be important steps in derisking an approach before its clinical development in 
humans. The anticipated costs for many of the approaches may however, be prohibitive for animal use. 
Commitment to substantial subsidies may be required to incentivise alternative development for animal health.  
5. Conventional antibiotics will still be needed. 
At least initially, many of the A2As are likely to be trialled and used as adjuncts to antibiotics because their 
activities may be insufficient to provide sufficient therapeutic benefit on their own. While effective antibiotics 
are still available it may prove difficult to demonstrate superiority of standard of care when comparing an 
antibiotic with an antibiotic plus an A2A adjunct treatment. If resistance to the antibiotic develops, then its use 
in combination therapies will be compromised. In the longer term, it may be possible to demonstrate that 
combinations of A2A therapies could be used without antibiotics. 
6. We anticipate that deployment of Alternatives will: 
I. Entail reliance on improved and faster diagnostic technology to enable targeting of individual bacterial 
species, or even strains of species, rather than clinical indications 
II. Be more often used for prophylaxis than for treatment 
III. Require of multiple products to replace a single antibiotic 
IV. Substantially higher costs than for traditional antibiotics 
V. Require access to sufficient and sustained funding to enable timely R&D and prompt clinical 
evaluation. 
 
Future outlook 
The working party recognised that academic researchers and industry have successfully generated a diverse 
portfolio of potential A2As comprising projects from preclinical optimisation to Phase III studies and prioritised 
10 approaches for more detailed review. The field is still emerging and holds promise provided that adequate 
funding is available to build capacity, a preclinical evidence-base is created to enable prioritisation and to 
progress optimised drugs to critical Phase II validation of innovative approaches.  
There was little doubt that the field might deliver new medicines for P. aeruginosa, S. aureus and C. difficile. 
However, other than probiotics for C. difficile, this first wave of new agents is likely to serve best as adjunctive 
or preventive therapy. Therefore, traditional antibiotics will still be required.  
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If we have to depend on A2As in the future, we need to build capacity now and increase substantially the 
throughput of projects103. The working party estimated that the priority approaches alone require an investment 
of at least £1.5bn, committed in the next 5 years and spent within 10 years to initiate a pipeline of translational 
projects that would deliver these new therapies. Longer term significant and sustainable funding will be required 
to advance and exploit the wider A2A portfolio. Policy and funding must now be linked. Without adequate 
funding we must assume that new treatments to replace and/or supplement antibiotics will not be available for 
more than a decade if at all. Our analysis of just a subset of all of the activities that could contribute towards the 
fight against antimicrobial resistance suggests that funding is now the key limiting factor that is stalling a global 
response. Antimicrobial resistance has to become a major international science programme in order to deliver 
the solutions that society needs now. By comparison the Large Hadron Collider project cost ~£6bn and the 
International Space Station  £96bn. Antimicrobial research probably requires an effort somewhere between the 
two.  
Key Messages (as a text box) 
• Alternatives to antibiotics: Non-compound approaches that target bacteria or approaches that target the 
host to treat infection 
• Academics and industry have created at least 20 approaches that need to be further evaluated 
• Understanding the potential of A2A will require experimental clinical medicine and not just drug 
discovery 
• Enhanced translational expertise must be deployed to aid validation and progression of these A2As 
• Exemplar projects must be advanced to II to enable clinical validation of approaches 
• Antimicrobial resistance needs to grow into big science to deliver major new innovative therapies 
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Tables 
Table 1. Prioritised alternative approaches 
Alternative 
Approach 
Comment Likely 
spectrum of 
activity and 
initial use 
Recommendation 
over the next 5 
years 
Refs 
Tier 1 (Primarily translational - funding to clinical evaluation at Phase 2)  
Antibodies Antibodies that bind to and inactivate a pathogen, its virulence 
factors, or its toxin(s) were widely considered one of the alternative 
approaches most likely to have major clinical impact. Antibodies 
were considered a relatively low risk area with strong underpinning 
science, safe history of use, and a high degree of technical feasibility. 
Prevent 
G+ and  G- 
infection, 
possibly also 
adjunct use 
Basic R&D and 
Translational 
2, 4–
7 
Probiotics Probiotics are defined as “live microorganisms which when 
administered in adequate amounts confer a health benefit on the host 
organism”. It is considered likely that defined mixtures of bacteria or 
the use of non-toxigenic spores of C. difficile will provide 
therapeutic and prophylactic therapies that will improve on current 
clinical practice for the treatment of CDAD/AAD.  Basic research to 
understand the mechanism of action of probiotics in different settings 
and how they might be used in combination with antibiotics and 
other A2As e.g. bacteriophages could enable their wider use in other 
indications. 
Prevent 
or treat 
CDAD/AAD 
Translational 8–13 
Lysins Phage lysins are enzymes used by bacteriophages to destroy the cell 
wall of a target bacterium and are potential replacements for 
antibiotics because of their direct antibacterial action, and also as 
adjuncts because they act to reduce bacterial burden and/or weaken 
biofilms. Emphasis on Lysins active against Gram-ve pathogens 
would be beneficial. 
Treat G+ 
infection 
Basic R&D and 
Translational 
14–
21 
Wild-type 
Bacteriophages 
Wild-type bacteriophage that infect and kill bacteria have the  
potential to replace antibiotics for some indications. Bacteriophage 
may be used in a comparatively small dose because they replicate 
when their host bacterium is present. During treatment of an 
infection they also evolve to infect the strains causing the disease. 
This replication and evolution makes them unique in pharmaceutical 
product development. In terms of pharmacology, the subject 
experiences more product than was dosed and that product can 
change over time so that what is sampled after dosing is not exactly 
what was given to the patient. 
Treat 
G+ and G- 
infection 
Basic R&D and 
Translational 
22–
26 
Engineered 
Bacteriophages 
The ability to genetically engineer to produce a new phage for 
therapeutic use is strong. Early indications are that many of the 
challenges associated with mixtures of wild-type phage, such as 
breadth of strain coverage, development of resistance, and rapid 
elimination after systemic administrationcould be addressed. One of 
the advantages of non-replicating phage might be in dose selection 
but there could be issues with manufacturing the larger doses 
required. Higher doses may also result in a greater host immune 
response which could limit the use of non-replicating phage to 
once/lifetime. One disadvantage could be that non-replicating phage 
cannot evolve during the course of treatment. 
Treat 
G+ and G- 
infection 
Basic R&D and 
Translational 
27–
30 
Immune 
Stimulation 
Successful antimicrobial therapy depends on a supportive immune 
response. Immune stimulation has been proposed as a potential 
adjunct approach in conjunction with broad-spectrum antibiotic 
therapy. Re-purposing of phenyl butyrate and vitamin D to enhance 
expression of natural antimicrobial peptides seems feasible.  
Oral bacterial extracts are registered and used clinically to reduce the 
incidence of respiratory tract infections in some at risk groups in 
some regions. If successful, additional clinical trials to confirm their 
efficacy in other populations would encourage wider use. 
Prevent or 
provide 
adjunct 
therapy for 
G+ and G- 
infection 
Basic R&D and 
Translational 
31–
37 
Vaccines With potential to substantially reduce the incidence of infection and 
therefore the need to use antibiotics, the long established investment 
in vaccines for new targets should continue. Given the ageing human 
population, we need better knowledge of the potential for 
vaccination in the elderly and how to dose to achieve protection in 
immune compromised individuals. 
Prevention, 
G+ more 
than G- 
infection 
Basic R&D, esp. 
on new adjuvants 
38–
52 
Tier 2 (strong support for judicious funding while monitoring for breakthrough insights) 
Antimicrobial 
Peptides 
(AMPs) 
The advantages of AMPs are their broad spectrum activity which 
includes most major Gram-negative and Gram-positive bacteria; 
their bactericidal and rapid action; low target-based resistance and 
their lack of immunogenicity. The extensive academic literature has 
Treat or 
Adjunct for 
G+ and G- 
infection 
Translational 53–
61 
Lancet ID Manuscript July 2015 10 of 17 
not led to therapeutic breakthrough for systemic treatments. 
Host/Innate 
Defense 
Peptides 
(HDPs/IDRs) 
Host defense peptides and innate defense regulators are small natural 
peptides or synthetic peptides respectively, which have indirect 
antimicrobial effects. They act primarily by increasing expression of 
anti-inflammatory chemokines and cytokines, and by reducing the 
expression of pro-inflammatory cytokines. Additional resources are 
required to accelerate their preclinical evaluation and progression 
into clinical trials to provide clinical validation of the approach 
Adjunct for 
G+ and G- 
infection 
Basic R&D 62, 
63 
Antibiofilm 
Peptides 
Peptides that specifically inhibit bacterial biofilm formation have 
been identified and are in preclinical development. Their use as 
adjunctive therapy could improve outcomes 
Adjunct for 
G+ and G- 
infections 
Basic R&D 64 
G+ = Gram-positive, G- = Gram-negative, Basic R&D = provide support for fundamental research and 
preclinical proof of concept studies to validate approaches and extend into early translational work to 
characterise efficacy, pharmacology, pharmacodynamics and preliminary toxicology so that  potential liabilities 
can be defined. Translational = focus support on bringing products into the clinic.  
Table 2: Additional alternative approaches 
Alternative Approach Comment Refs 
Immune Suppression A bacterial infection can lead to an excessive host innate immune response (ranging from the 
systemic inflammatory response syndrome (SIRS) to septic shock) in which the injury to the host is 
made much worse by the host’s pro-inflammatory cytokine response.  Selective manipulation of this 
cytokine response has the potential to be used in synergy with antibiotics to reduce pathogen 
induced but cytokine and neutrophil mediated tissue damage, and to accelerate the time to patient 
recovery. The medical need is high but past failures of Phase III clinical trials, despite promising 
preclinical and Phase I or Phase II data, means that this area of sepsis and septic shock has not been 
prioritised. New concepts are therefore needed to develop novel small as well as large molecule 
drugs for this high mortality area of infection whose incidence is increasing. In contrast to 
antibiotics, the healthcare sector would pay a large premium for a drug that was effective at 
reducing morbidity and mortality     
65–67 
Anti-resistance 
nucleic acids 
Antibiotic resistance genes are frequently spread by highly contagious plasmids, particularly in 
Gram-negative pathogens. Effective removal of resistance genes could resensitise bacteria to 
conventional antibiotics. The approach may present substantial technical and regulatory challenges.  
68–73 
Antibacterial nucleic 
acids 
The use of nucleic acids to directly kill bacteria is being explored in a variety of formats in both 
academia and biotech. In terms of their therapeutic potential, studies are at an early stage. At the 
very least, these tools will continue to be developed to support fundamental microbial genetics 
studies. 
72–74 
Toxin sequestration 
using liposomes 
Pathogens often secrete toxins that damage mammalian cells and drive inflammation. 
Administration of liposomes to act as decoys for toxin binding has been shown to reduce damage to 
cells and reduce disease severity. 
75 
Antibiotic-degrading 
enzymes to reduce 
selection of 
resistance 
When antibiotics are eliminated via the gut, exposure of the normal gut bacteria to the antibiotic 
may lead to development of resistance and drive CDAD/AAD. Phase 2 studies demonstrate that oral 
beta-lactamase can destroy the beta-lactam in the fecal stream. The clinical challenge of 
demonstrating these clinical effects at Phase III meant that this area was not prioritised 
76-79 
Metal Chelation Bacterial pathogens require zinc, manganese and iron ions to fully express their 
pathogenicity/virulence, biofilm formation and multiple essential enzymatic and metallo-beta 
lactamase activities. Metal chelation may deny pathogens these key processes. Discussion with 
pharmacologists and toxicologists suggests that this approach is speculative and could present safety 
concerns 
81-84 
Alphamers  Alphamers are immune modifiers comprising an α-Gal epitope fused to a bacterial pathogen binding 
aptamer to redirect endogenous anti-Gal antibodies to the pathogen and hence enhance immune 
clearance. 
85 
Transcriptional 
regulatory 
compounds 
The use of compounds to modify transcriptional regulation can resensitise pathogens to antibiotics 
e.g. the use of EthR-binding compounds to derepress expression of the ethA gene, a mono-
oxygenase that activates ethionamide in M. tuberculosis. The compound sensitises some strains of 
M. tuberculosis to ethionamide 
86 
Apheresis of 
protective antibodies 
In some patients with P. aeruginosa lung infection, antibodies bind to the pathogen and protect it 
from serum-mediated killing. Depletion of these antibodies restores the ability of serum to kill 
bacteria and initial clinical data suggest an improved clinical outcome. 
87 
Immune Stimulation 
by P4 Peptide 
Phagocytic killing of bacteria can be enhanced by P4 Peptide, a chemically synthesised 28 amino 
acid peptide derived from the S. pneumoniae surface exposed virulence factor PsaA. P4 peptide 
stimulates opsonophagocytic uptake and killing in invasive disease models of S. pneumoniae 
infection in mice. The combination of P4 intranasally and i.p. IgG provided 100% survival in the 
mouse model and significantly reduced bacterial burden. A therapy based on P4, IgG and antibiotic 
is proposed. However, additional evidence may be required to support the use of iv IgG in severe 
pneumonia. The project recently received MRC DPFS funding to progress to Phase I studies. 
88, 89 
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Table 3. A2A Portfolio Review as at Q1 2015 
Approach Probability of 
Registration by 
2025+  and Sponsor 
Risk Adjusted 
Cost of Projects  
(current/subsequent 
phases) 
and Target 
Recommended pipeline 
investment to enable 
additional Phase 2 
validation#  
and Name 
Phase at Q1 2015 Earliest 
Anticipated 
Registration* 
Antibodies 170%+ £54m/£106m -   
 Merck C. difficile MK-3415A P3 ongoing 2017 
 MedImmune  S. aureus MEDI4893 P2 ongoing 2021 
 Aridis P. aeruginosa AR-101 P2a complete 2021 
 Aridis S. aureus AR-301 P2a ready 2022 
 MedImmune P. aeruginosa  MEDI3902 P1 ongoing 2023 
 Aridis P. aeruginosa Aerucin IND ready 2025 
Probiotics 124%+ £52m/£53m -   
 Seres C. difficile SER-109 P3 ready 2018 
 Rebiotix C. difficile RBX2660 P2 ongoing 2019 
 Shire (Viropharma) C. difficile VP20621 P2 ready 2022 
Lysins 26%+ £12m/£28m £135m   
 Intron Biotechnology S. aureus SAL200 P1 ongoing 2022 
 Contrafect S. aureus CF-301 P1 ready 2022 
Bacteriophages 9%+ £13m/£57m £135m   
Wild-type      
 AmpliPhi C. difficile AmpliPhage-004 Pre-P1 2023 
 AmpliPhi P. aeruginosa AmpliPhage-001 Pre-P1 2023 
Engineered      
 Phico Therapeutics P. aeruginosa PT-3.1 Pre-P1 2024 
Immune 
Stimulation 
43%+ £0m/£55m -   
 Akthelia C. difficile Phenylbutyrate/vitD P2 ready 2021 
 - Various Bacterial extracts P1 ready 2022 
Vaccines 188%+ £74m/£66m -   
 Sanofi Pasteur C. difficile C. difficile toxoid vaccine P3 2019 
 Valneva P. aeruginosa IC43 P2/P3 ongoing 2019 
 Valneva C. difficile IC84 P2 ongoing 2021 
 Pfizer S. aureus SA4Ag P2 ready 2021 
Antimicrobial 
Peptides 
52%+ £16m/£104m £135m   
 Roche P. aeruginosa POL7080 P2 ongoing 2022 
 Novacta Biosystems C. difficile NBV302 P1 ongoing 2022 
 Adenium S. aureus AP-138 Pre-P1 2023 
 Adenium UTI AP-139 Pre-P1 2023 
 Adenium C. difficile AP-114 Pre-P1 2023 
Other Peptides - - £575m   
 - Gram-ve and 
Gram+ve 
- Preclinical 2027 
 
Table 4: Estimate of the project pipeline cost for Host Defence and Antibiofilm peptides 
Phase Preclinical Phase I Phase II Phase III Registration Total 
Stage probability of success 23% 45% 47% 71% 90%  
Number of projects 34 8 4 2 1  
Cost of Phase £m 12.5 6 10 45 1.3  
Portfolio cost £m 425 48 40 90 1.3 £575 
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